4D Molecular Therapeutics (NASDAQ:FDMT) Sees Strong Trading Volume - Here's Why

Key Points

• Trading activity increased in focus: About 733,855 FDMT shares changed hands, down 12% from the prior session, while the stock traded at $14.128 versus a previous close of $14.47.
• Analyst sentiment is broadly positive: The stock has a consensus “Moderate Buy” rating and a $28.56 average price target, although ratings range from Strong Buy to Sell.
• Financial results remain pressured: 4D Molecular Therapeutics posted a quarterly loss of $1.04 per share, slightly missing estimates, despite revenue of $3.78 million exceeding expectations. Insiders have sold shares recently, while institutional investors own 99.27% of the company.

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) saw an uptick in trading volume on Monday. Approximately 733,855 shares traded hands during trading, a decline of 12% from the previous session's volume of 837,695 shares. The stock last traded at $14.1280 and had previously closed at $14.47.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Chardan Capital raised shares of 4D Molecular Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. Cantor Fitzgerald raised 4D Molecular Therapeutics from a "neutral" rating to an "overweight" rating and set a $20.00 target price on the stock in a research report on Monday, September 14th. B. Riley Financial reissued a "buy" rating on shares of 4D Molecular Therapeutics in a research report on Monday, August 17th. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $28.56.

4D Molecular Therapeutics Price Performance

The company's 50 day moving average price is $13.17 and its 200-day moving average price is $11.08. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03. The company has a market cap of $802.31 million, a price-to-earnings ratio of -5.53 and a beta of 2.74.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The company had revenue of $3.78 million for the quarter, compared to analysts' expectations of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. On average, equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.07 earnings per share for the current fiscal year.

Insider Transactions at 4D Molecular Therapeutics

In related news, insider David Kirn sold 58,333 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $13.90, for a total value of $810,828.70. Following the transaction, the insider directly owned 767,486 shares in the company, valued at $10,668,055.40. This represents a 7.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 134,570 shares of company stock worth $1,743,197. Corporate insiders own 7.90% of the company's stock.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of FDMT. Persistent Asset Partners Ltd bought a new stake in shares of 4D Molecular Therapeutics during the second quarter worth about $1,936,000. Deutsche Bank AG bought a new stake in 4D Molecular Therapeutics during the 2nd quarter worth approximately $9,456,000. Dimensional Fund Advisors LP grew its position in 4D Molecular Therapeutics by 77.3% during the first quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company's stock valued at $4,863,000 after acquiring an additional 227,982 shares during the last quarter. Exome Asset Management LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 1st quarter worth about $1,216,000. Finally, Bank of America Corp DE increased its stake in shares of 4D Molecular Therapeutics by 17.0% during the first quarter. Bank of America Corp DE now owns 974,173 shares of the company's stock valued at $9,070,000 after purchasing an additional 141,582 shares in the last quarter. Institutional investors own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.